Welcome to our dedicated page for Affimed N.V. news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed N.V. stock.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company headquartered in Mannheim, Germany, with additional offices in New York, NY. Affimed is dedicated to leveraging the power of the innate immune system to develop innovative immuno-oncology therapies primarily aimed at treating various cancers. The company is at the forefront of developing its proprietary innate cell engagers (ICE®), which are designed to target and eliminate both hematologic and solid tumors.
At the core of Affimed's innovation is their ROCK® platform, a state-of-the-art technology that generates customized ICE® molecules. These molecules harness the natural power of immune cells, such as natural killer (NK) cells and T-cells, to target and destroy cancer cells. Affimed's lead products include AFM13 (acimtamig), AFM24, and AFM28, which are currently undergoing various stages of clinical trials.
AFM13, the company's flagship innate cell engager, shows promise in treating CD30-positive hematologic tumors. It has demonstrated significant clinical efficacy in heavily pretreated patients with refractory Hodgkin lymphoma, achieving high objective response rates (ORR) and complete response (CR) rates. AFM13 is being investigated in combination with NK cells in the LuminICE-203 study, with initial data expected in the first half of 2024.
AFM24 is another key candidate, targeting EGFR-expressing solid tumors. It is currently being tested in combination with atezolizumab, a checkpoint inhibitor, in the AFM24-102 Phase 1/2a study. Recent data showed a disease control rate of 73.3% in heavily pretreated patients with EGFR wild-type non-small cell lung cancer (NSCLC), including significant objective responses. The FDA has granted Fast Track designation for this combination therapy, highlighting its potential to meet unmet medical needs.
AFM28 targets CD123-positive acute myeloid leukemia (AML). Preclinical studies have shown that AFM28 can effectively reduce tumor growth and eliminate leukemic blasts and stem cells. The drug is currently in early clinical development, with future plans to test it in combination with allogeneic off-the-shelf NK cells.
Affimed is also committed to strategic collaborations and partnerships to advance its clinical programs. Notable collaborations include those with Artiva Biotherapeutics, The University of Texas MD Anderson Cancer Center, and Roche. These partnerships are aimed at enhancing the efficacy and safety profiles of Affimed's therapies and bringing innovative treatments to patients more quickly.
Despite facing challenges such as restructuring and a reduction in workforce, Affimed remains focused on advancing its clinical pipeline. The company's strong leadership team, extensive experience in biotechnology and pharmaceuticals, and a clear mission to revolutionize cancer treatment underscore its commitment to giving patients back their innate ability to fight cancer.
For more information about Affimed's people, pipeline, and ongoing projects, please visit www.affimed.com.
Affimed N.V. (Nasdaq: AFMD) announced the appointment of Ms. Uta Kemmerich-Keil to its Supervisory Board, effective immediately from June 15, 2021. Approved during the Annual General Meeting, her extensive experience in the life sciences sector, particularly in leading global pharmaceutical companies, positions her to provide significant guidance in advancing Affimed's immuno-oncology pipeline. Kemmerich-Keil previously held senior roles at companies like P&G and Merck KGaA, bringing valuable financial and strategic expertise to Affimed’s growth strategy.
Affimed N.V. (Nasdaq: AFMD) announced that its CEO, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:30 a.m. Eastern Time.
A live webcast can be accessed on Affimed’s website, with an archived replay available for 30 days post-event.
Affimed is focused on immuno-oncology and utilizes its proprietary ROCK® platform to harness the innate immune system in cancer treatment, developing innovative therapies to target various tumors.
Affimed N.V. (Nasdaq: AFMD) announced that its 2021 Annual General Meeting (AGM) will take place on June 15, 2021, at 17:30 PM CET (11:30 AM EDT). In light of the ongoing COVID-19 pandemic, the meeting will be held virtually to ensure the safety of shareholders. Interested parties can access the meeting via the designated link. The notice and agenda for the meeting are accessible on the company’s website and the SEC’s website.
Affimed N.V. (Nasdaq: AFMD) announced promising preclinical results for AFM13, an innate cell engager (ICE®) targeting CD30-positive tumors. The data showed that AFM13 enhanced the efficacy of natural killer (NK) cells in recognizing and killing tumor cells both in vitro and in vivo. This supports the ongoing Phase I clinical trial of AFM13 pre-complexed with NK cells. Notably, early Phase 1 data revealed a 100% objective response rate among heavily pretreated patients, with no severe side effects reported. These findings highlight AFM13's potential as an innovative cancer treatment.
Affimed N.V. (Nasdaq: AFMD) reported positive interim results for its AFM13 monotherapy study in PTCL, achieving a 100% objective response rate in four evaluable patients, including two complete responses. The company also provided updates on clinical trials for AFM24, including a cleared IND application for its combination with NKGen's SNK-01. Financially, Affimed showed a pro forma cash position of approximately €244.5 million as of December 31, 2020, which supports operations through mid-2023. Total revenue rose to €28.4 million in 2020, driven largely by collaborations with Genentech and Roivant.
Affimed N.V. (Nasdaq: AFMD) has announced promising pre-clinical data for its Innate Cell Engager (ICE®) AFM24, demonstrating significant tumor cell killing capabilities independent of KRAS mutations. Presented at the AACR Virtual Annual Meeting, AFM24 shows potential in combination with adoptively transferred NK cells, leading to dose-dependent tumor regression. This innovative mechanism may change the treatment landscape for EGFR-expressing solid tumors. The company continues to evaluate AFM24 for patients with advanced malignancies, supported by regulatory approvals for ongoing clinical trials.
Affimed N.V. (Nasdaq: AFMD) announced promising initial results from a Phase 1 trial at MD Anderson, showcasing a 100% objective response rate in four patients with recurrent/refractory CD30-positive lymphomas. Among these, two achieved complete responses and two had partial responses. Importantly, there were no signs of cytokine release syndrome or neurotoxicity. The trial, which utilizes cord blood-derived NK cells pre-complexed with Affimed's AFM13, is continuing to enroll patients for further cohorts. A conference call is scheduled for April 14 to discuss these findings.
Affimed N.V. (Nasdaq: AFMD) will report its 2020 financial results and corporate updates on April 15, 2021, with a conference call at 8:30 a.m. EDT. Investors can join via phone or webcast, accessing the call with specific dial-in numbers and a conference ID.
Affimed is focused on immuno-oncology, leveraging its proprietary ROCK® platform to develop therapies aimed at treating various tumors. The company aims to empower patients' innate immunity to combat cancer effectively.
Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc. announced the FDA's clearance of an IND for a Phase 1/2a study. This trial will explore the combination of AFM24, an EGFR/CD16A innate cell engager, with SNK-01, an autologous NK-cell product, targeting solid tumors expressing EGFR. The aim is to improve treatment outcomes for patients who have failed conventional therapies. The study will assess safety, pharmacokinetics, and preliminary efficacy, marking a significant step for both companies in advancing innate immunity-based therapies.
Affimed N.V. (Nasdaq: AFMD) announced that preclinical data on AFM24 will be showcased via e-poster at the AACR Virtual Annual Meeting I from April 10-15, 2021. The poster presents AFM24 as a potent bispecific innate cell engager targeting EGFR for cancer treatment. Additionally, AFM13 data will be highlighted in a symposium on April 13, focusing on its use in combination with NK cells for treating CD30-expressing lymphomas. These presentations aim to advance understanding of the efficacy of these therapies in oncology.
FAQ
What is the current stock price of Affimed N.V. (AFMD)?
What is the market cap of Affimed N.V. (AFMD)?
What does Affimed N.V. specialize in?
What is the ROCK® platform?
What are Affimed's key clinical candidates?
What is AFM13 used for?
What is the significance of AFM24's Fast Track designation?
How does AFM28 work?
What collaborations does Affimed have?
Where is Affimed N.V. headquartered?
What are the recent achievements of Affimed?
What is the company's mission?
